Hydrocortisone Fails to Make a Dent in Septic Shock Deaths

Hydrocortisone Fails to Make a Dent in Septic Shock Deaths | Medpage Today:

But does chip away at need for blood transfusion, ADRENAL trial shows

Glucocorticoid therapy made no difference in the risk of mortality for mechanically-ventilated patients in septic shock, the ADRENAL trial reported.

At 90 days, mortality reached 27.9% of those randomized to a continuous infusion of hydrocortisone (200 mg daily for 7 days) and 28.8% of peers getting a placebo (OR 0.95, 95% CI 0.82-1.10). The lack of difference was observed across prespecified subgroups, according to a group led by Balasubramanian Venkatesh, MD, of Australia's Wesley Hospital.